Sign In
Buy ARCT
$5.76
-0.160 (-2.70%)
At Close: Jul 31, 2026
Arcturus' mRNA Platform: The Future Of Quick And Efficient Vaccine Delivery
04:01am, Wednesday, 01'st Feb 2023
Arcturus is revolutionizing biotechnology with its cutting-edge mRNA vaccines and delivery systems. They recently teamed up with CSL Seqirus, a leading player in the flu vaccine industry.
Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
08:30am, Monday, 19'th Dec 2022
SAN DIEGO--( BUSINESS WIRE )--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the develop
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2022 Earnings Call Transcript
09:11pm, Wednesday, 09'th Nov 2022
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q3 2022 Results Conference Call November 9, 2022 4:30 PM ET Company Participants Kyle Gutsadt - Investor Relations Joseph Payne - President and Chief
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Tops Revenue Estimates
06:48pm, Wednesday, 09'th Nov 2022
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 33.83% and 281.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the st
Arcturus Therapeutics to Present at the Following Investor Conferences in November
05:00pm, Monday, 07'th Nov 2022
SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the developm
Arcturus Therapeutics (ARCT) Surges 18.7%: Is This an Indication of Further Gains?
06:47am, Friday, 04'th Nov 2022
Arcturus Therapeutics (ARCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strengt
Why Arcturus Therapeutics Stock Is Skyrocketing Today
12:00pm, Wednesday, 02'nd Nov 2022
Investors are applauding Arcturus' collaboration with CSL.
Why Is Arcturus Therapeutics (ARCT) Stock Up 30% Today?
11:06am, Wednesday, 02'nd Nov 2022
A strategic collaboration has today's traders talking about Arcturus Therapeutics (NASDAQ: ARCT ) and CSL (OTCMKTS: CSLLY ). Reportedly, the two companies will work together on mRNA technology for a w
Arcturus Therapeutics to Attend the Following Investor Conferences
06:00pm, Tuesday, 27'th Sep 2022
SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage messenger RNA medicines company focused on the development of in
7 Small-Cap Stocks to Buy on the Dip or You'll Be Kicking Yourself Later
12:28pm, Thursday, 22'nd Sep 2022
With several worrying developments domestically and internationally, many investors chose to rush for the exits, though a brave few may have opportunities in small-cap stocks to buy on the dip. Tether
Acrturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q2 2022 Results - Earnings Call Transcript
10:41pm, Tuesday, 09'th Aug 2022
Acrturus Therapeutics Holdings Inc. Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Joseph Payne - President and Chief Executive Officer Andrew Sassine - Chief Financia
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates
06:48pm, Tuesday, 09'th Aug 2022
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 55.43% and 714.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Arcturus: Potential Based On Rare Disease Therapy ARCT-810
11:04pm, Monday, 06'th Jun 2022
An EUA for ARCT-154 as a COVID-19 vaccine in Vietnam has been submitted, with expected approval in 2022. A phase 2 study using ARCT-810 as a treatment option for patients with OTC deficiency is expect
Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q1 2022 Results - Earnings Call Transcript
11:09pm, Monday, 09'th May 2022
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q1 2022 Results Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Deepankar Roy - Senior Director, Investor Relations Joseph Payne
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates
06:49pm, Monday, 09'th May 2022
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -50.39% and 60.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
